First line treatment of T315I mutation in CML management is?
Correct Answer: Ponatinib
Description: T315I mutation is a mutation in the critical BCR-ABL kinase in the ATP-binding pocket This prevents imatinib binding and hence leads to resistance to imatinib, nilotinib, bosutinib, and dasatinib. Only drug effective for T315I mutation CML = Ponatinib. Otherwise DOC CML= Imatinib. DOC for Imatinib resistant CML = Bosutinib DOC in case of failure of > 2 Tyrosine kinase inhibitor = OMACETAXINE
Category:
Medicine
Get More
Subject Mock Tests
Practice with over 200,000 questions from various medical subjects and improve your knowledge.
Attempt a mock test nowMock Exam
Take an exam with 100 random questions selected from all subjects to test your knowledge.
Coming SoonGet More
Subject Mock Tests
Try practicing mock tests with over 200,000 questions from various medical subjects.
Attempt a mock test now